21962-53-8

Usage

Uses

Used in Organic Synthesis:
5-Cyano-2-methoxybenzaldehyde is utilized as a building block in the preparation of various pharmaceuticals and other organic compounds. Its unique structure allows for the creation of a wide range of molecules with diverse properties and applications.
Used in Pharmaceutical Development:
5-cyano-2-methoxybenzaldehyde is employed as a key intermediate in the synthesis of drugs, owing to its ability to participate in various chemical reactions and form heterocyclic compounds. Its presence in the molecular structure can influence the pharmacological properties of the final product.
Used in Chemical Reactions:
5-Cyano-2-methoxybenzaldehyde serves as a reagent in chemical reactions, particularly in the formation of heterocyclic compounds. Its reactivity and functional groups make it a valuable component in the synthesis of complex organic molecules.
Used in Antimicrobial Applications:
5-Cyano-2-methoxybenzaldehyde has been studied for its potential antimicrobial properties, making it a candidate for use in the development of new antimicrobial agents to combat resistant strains of bacteria.
Used in Anticancer Research:
5-cyano-2-methoxybenzaldehyde has also been investigated for its potential anticancer properties, indicating that it could be a promising candidate for further research and development in oncology.

Upstream product

• 544-92-3 copper(I) cyanide 
• 25016-01-7 5-bromo-2-methoxybenzaldehyde 
• 557-21-1 dicyanozinc 
• 67-56-1 methanol 
• 146137-79-3 4-fluoro-3-formylbenzonitrile 
• 124-41-4 sodium methylate 
• 121124-97-8 3-formyl-4-methoxyphenylboronic acid 
• 7677-24-9 trimethylsilyl cyanide 
• 101207-62-9 3-bromomethyl-4-methoxybenzonitrile 
• 135-02-4 ortho-anisaldehyde 

Downstream Products

• 914106-06-2 5-cyano-2-methoxybenzaldehyde chlorooxime 
• 914106-24-4 3,5-bis(5-cyano-2-methoxyphenyl)isoxazole 
• 1613334-79-4 (Z)-3-(2-cyano-2-(6-methoxy-1H-indol-3-yl)vinyl)-4-methoxybenzonitrile 
• 1338081-25-6 (Z)-4-methoxy-3-((2-methyl-5-oxooxazol-4(5H)-ylidene)methyl)benzonitrile 
• 1338081-27-8 (Z)-3-((1,2-dimethyl-5-oxo-1H-imidazol-4(5H)-ylidene)methyl)-4-hydroxybenzonitrile 

Relevant academic research and scientific papers

2-arylamine-4-amido quinazoline compound as well as preparation method and application thereof

The invention provides a 2-arylamine-4-amido quinazoline compound and a preparation method thereof. The 2-arylamine-4-amido quinazoline compound is shown in a formula I. The compound in the formula I has good inhibitory activity on EGFR L858R/T790M/C797S kinase and can be used for preparing drugs for treating diseases or symptoms related to tumors.

Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Inhibition of the epidermal growth factor receptor (EGFR) has been proved to be one of the most promising strategies for the treatment of non-small cell lung cancers. A series of 2-aryl-4-amino substituted quinazoline derivatives were designed and synthesized with the purpose to overcome L858R/T790M/C797S (CTL) triple mutant drug resistance and the biological activity for inhibition of CTL kinases and EGFR wild type (WT) were evaluated. Three compounds (20, 24 and 27) showed excellent inhibitory activities against EGFR kinases triple mutant CTL (IC5050: WT/CTL >10000). Cell line evaluation showed that the most potent compound 27 was significantly potent against H1975-EGFR L858R/T790M (IC50=3.3μM) and H1975-EGFR L858R/T790M/C797S (IC50=1.2μM). Compound 27 also exhibited good microsomes stabilities in human, rat and mouse liver species, but low bioavailability. This work would be very useful for discovering new quinazoline derivatives as tyrosine kinase inhibitors targeting triple mutant L858R/T790M/C797S.

Design, synthesis and biological evaluation of antimicrobial diarylimine and –amine compounds targeting the interaction between the bacterial NusB and NusE proteins

Discovery of antimicrobial agents with a novel model of action is in urgent need for the clinical management of multidrug-resistant bacterial infections. Recently, we reported the identification of a first-in-class bacterial ribosomal RNA synthesis inhibitor, which interrupted the interaction between the bacterial transcription factor NusB and NusE. In this study, a series of diaryl derivatives were rationally designed and synthesized based on the previously established pharmacophore model. Inhibitory activity against the NusB-NusE binding, circular dichroism of compound treated NusB, antimicrobial activity, cytotoxicity, hemolytic property and cell permeability using Caco-2 cells were measured. Structure-activity relationship and quantitative structure–activity relationship were also concluded and discussed. Some of the derivatives demonstrated improved antimicrobial activity than the hit compound against a panel of clinically important pathogens, lowering the minimum inhibition concentration to 1–2 μg/mL against Staphylococcus aureus, including clinical strains of methicillin-resistant Staphylococcus aureus at a level comparable to some of the marketed antibiotics. Given the improved antimicrobial activity, specific inhibition of target protein-protein interaction and promising pharmacokinetic properties without significant cytotoxicity, this series of diaryl compounds have high potentials and deserve for further studies towards a new class of antimicrobial agents in the future.

SUBSTITUTED 5-METHYL-[1, 2, 4] TRIAZOLO [1,5-A) PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS

The invention provides a chemical entity of Formula (I): (I), wherein R1, R2, R3, and R4, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma- dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES

The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.

Copper(I)-mediated cyanation of boronic acids

A simple cyanation reaction of boronic acids with cuprous cyanide is achieved, providing nitriles in moderate to good yields. In the presence of copper(I) iodide, trimethylsilyl cyanide is also a good cyanating reagent. The reaction can be conducted on a 10-mmol scale. Thus, this new approach represents an exceedingly practical method for the synthesis of nitriles.

Statistical experimental design-driven discovery of room-temperature conditions for palladium-catalyzed cyanation of aryl bromides

A combination of Pd2(dba)3·CHCl3 (0.5 mol %) and commercially available, air-stable phosphonium salt [(t-Bu) 3PH]BF4 (1.4 mol %) in a presence of Zn powder and Zn(CN)2 as the cyanide source comprises an extremely efficient catalyst system for the cyanation of a diverse array of aryl bromides, at room temperature. This result emerged from an experimental strategy that combines the advantages of parallel, automated experimentation with the design of experiments (DOE) for the effective definition of an optimal set of reaction conditions.

Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same

The invention relates to benzofuran or benzothiophene derivatives of general formula: 1These compounds are of use as medicinal products, in particular in the treatment of pathological syndromes of the cardiovascular system.

Pyridine derivatives, their production and use

Pyridine derivatives of the formula STR1 wherein the ring A stands for an optionally further substituted benzene ring; the ring B stands for an optionally substituted pyridine ring; Q stands for hydroxyl group, or OQ 1 or Q 1 wherein Q 1 stands for an optionally substituted aliphatic hydrocarbon group; and n denotes 0 or 1, or their salts, which have potassium.channel opening activity and are useful as therapeutic agents of circulatory diseases such as angina pectoris, hypertension, etc.

Substituent Control of Intramolecular Hydrogen Bonding in Formyl-Protonated o-Anisaldehydes: A Stable Ion and Semiempirical MO Investigation

o-Anisaldehyde and its 5-Br, 5-F, 5-CF3, 5-CN, 5-NO2, and 5-COMe derivatives are protonated at the formyl group in 1 : 1 SbF5-FSO3H/SO2 (or SO2ClF) to give persistent carboxonium ions as mixtures of Z and E geometrical isomers.The cyano, nitro, and acetyl substituents are also protonated, leading to dications and additional geometrical isomers in the nitro and acetyl cases.The carboxonium ions are predominantly in the Z,syn configuration, but with increased amounts of the E,anti configuration with increased electron withdrawal by the substituents.With 5-NO2H(+), Eisomers become more abundant than Z.The formyl protonated 2-(trifluoromethoxy)benzaldehyde shows a strong preference for the E configuration.The preference for the Z,syn form is attributed to intramolecular hydrogen bonding that becomes less favorable as electron density is withdrawn from the methoxyl oxygen.The log Z/E values correlate with differences in energy content of the isomers predicted in AM1 calculations, and the chemical shift of the hydroxyl proton of the carboxonium group correlates well with predicted charge on the proton.